Navigation Links
GENova issues clarifying press release
Date:9/12/2009

NEW YORK, Sept. 12 /PRNewswire-FirstCall/ - GENova Biotherapeutics Inc. ("GENova") clarified today information disseminated in previous press releases regarding the patents currently in GENova's IP portfolio.

GENova owns the rights to a range of drug targets and has filed patent application for all of them. The patents have not yet been approved and are therefore considered 'patents-pending'. It has been brought to GENova's attention that previous releases were not entirely clear on this issue and may have been misconstrued by some investors. Any statements made prior to this announcement which stated or implied that patents have been granted are incorrect and should not be relied upon in making investment decisions.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies.Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
10. PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... During ... disease to enamel erosion, and those dental problems can increase the risk of ... many pregnant women are failing to get the dental care they need. Agoura ...
(Date:1/17/2017)... ... January 17, 2017 , ... In the ... Activewear is a stand-out company for several differences from other mainstream brands. ... on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows ...
(Date:1/17/2017)... Florida (PRWEB) , ... January 17, 2017 , ... Kevin ... Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty and ... become a better version of themselves. What better way to commit to these changes ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... continuing education for EMS and firefighting professionals, has released four new continuing education ... new courses are taught live in an online classroom and meet the requirements ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... SHANGHAI , Jan. 18, 2017 In ... of revolution, which is where the Upgrade of ... year of the 13th Five-Year Plan for Economic and Social ... (the 13th Five-Year Plan), and the state council of ... the "13th Five-Year" national strategic emerging industry development plan, identifying ...
(Date:1/18/2017)... Invetech, the leading developer of ... , has announced a collaboration agreement with Erytech ... treatments for acute leukemia and other oncology indications ... will develop systems to enable the commercial-scale manufacture ... platform, which uses a novel technology to encapsulate ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
Breaking Medicine Technology: